ArticleCancer causes & control : CCC2025
Preferences of High-Risk HPV-Based Cervical Cancer Screening among Transgender Men and Gender Diverse People Assigned Female at Birth: A Cross-Sectional Study at a Single Academic Center.
Article in Cancer causes & control : CCC, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe purpose of this study was to evaluate the willingness of gender diverse people assigned female at birth with a cervix for different high-risk HPV (hrHPV) methods of cervical cancer screening (CCS). We examined provider-collected hrHPV, at-home, self-collected hrHPV, and in-clinic, self-collected hrHPV, as well as their impact on gender dysphoria and screening barriers.
methodsThis cross-sectional survey study was conducted in 2024 among transgender men, non-binary, genderqueer, and agender individuals at a single academic medical center. Data from 123 participants included demographics, gender dysphoria, screening barriers, past experiences, and willingness to receive hrHPV testing. Statistical analyses identified differences in gender dysphoria, barriers to CCS, past Pap test experiences, and hrHPV testing preferences via logistic regression analyses.
resultsMost transgender men (63%) preferred at-home, self-collected hrHPV, and 37% of transgender men were unwilling to provider-collected hrHPV. Gender diverse people with gender dysphoria preferred at-home, self-collected hrHPV (60%), while those without gender dysphoria preferred alternating at-home, self-collected and provider-collected hrHPV (38%). Logistic regressions showed 78% (p < 0.005) and 53% (p < 0.001) lower odds of provider-collected hrHPV for those with gender dysphoria and screening barriers, respectively. Our findings showed that the concealment of procedural steps (Adjusted Odds Ratio = 0.01, p < 0.02), use of gendered language (AOR = 0.17, p < 0.01), and misgendering (AOR = 0.31, p < 0.05) reduced the willingness to undergo provider-collected hrHPV. However, these experiences did not show a difference between self-collected hrHPV testing methods.
conclusionThis is one of the largest U.S. studies assessing the preferences for hrHPV testing among gender diverse people. Our findings emphasize that transgender men prefer at-home, self-collected hrHPV, which can reduce gender dysphoria and screening barriers. This underscores the need for patient-centered screening and gender-inclusive care to help reduce disparities in CCS among gender diverse people.
Indexed as
Identifiers
41454978What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.